Sodium estrone sulfate

The main ingredients of this product are: conjugated estrogen. Premarin (conjugated estrogen tablets) is an oral preparation containing a mixture of estrogens extracted from pregnant mare urine, which is a mixture of water-soluble estrogen sodium sulfate salts. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It also contains sodium sulfate conjugate, 17α-hydroequilin, 17α-estradiol and 17β-_hydroequilin.

Single dose of drugs (including conjugated estrogens and medroxyprogesterone acetate). Drug interaction data show that the pharmacokinetic profile is not altered when these two drugs are taken together. No other drug interaction studies involving conjugated estrogens have been conducted clinically. In vitro and in vivo studies have shown that estrogens are partially metabolized by cytochrome P4503A4 (CYP3A4). Therefore, both inducers and inhibitors of CYP3A4 can affect the metabolism of estrogen drugs. CYP3A4 inducers such as St. John's wort extract (Hypericum perforatum), phenobarbital, carbamazepine, rifampicin and dexamethasone can reduce estrogen plasma concentrations, which may lead to reduced therapeutic efficacy and/or changes in uterine bleeding. CYP3A4 inhibitors such as cimetidine, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice can increase estrogen plasma concentrations and cause adverse reactions.

The main ingredients of this product are: conjugated estrogen. Premarin (conjugated estrogen tablets) is an oral preparation containing a mixture of estrogens extracted from pregnant mare urine, which is a mixture of water-soluble estrogen sodium sulfate salts. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It also contains sodium sulfate conjugate, 17α-hydroequilin, 17α-estradiol and 17β-_hydroequilin.

Single dose of drugs (including conjugated estrogens and medroxyprogesterone acetate). Drug interaction data show that the pharmacokinetic profile is not altered when these two drugs are taken together. No other drug interaction studies involving conjugated estrogens have been conducted clinically. In vitro and in vivo studies have shown that estrogens are partially metabolized by cytochrome P4503A4 (CYP3A4). Therefore, both inducers and inhibitors of CYP3A4 can affect the metabolism of estrogen drugs. CYP3A4 inducers such as St. John's wort extract (Hypericum perforatum), phenobarbital, carbamazepine, rifampicin and dexamethasone can reduce estrogen plasma concentrations, which may lead to reduced therapeutic efficacy and/or changes in uterine bleeding. CYP3A4 inhibitors such as cimetidine, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice can increase estrogen plasma concentrations and cause adverse reactions.

This medicine contains a mixture of estrogens extracted from pregnant mare urine, which is a mixture of water-soluble sodium sulfate salts of estrogen. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It also contains sodium sulfate conjugate, 17alpha;-dihydroequilin, 17alpha;-estradiol, and 17beta;-dihydroequilin.

Drug/laboratory test interactions: 1 Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factor II, factor VII antigen, factor VIII antigen, factor VIII aggregation activity, factor IX, X, XII, VII-X complex, II-VII-X complex, beta; thromboglobulin; decreased anti-Xa and antithrombin III levels, decreased antithrombin III activity; increased fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. 2 Increased thyroid binding globulin (TBG) can increase total circulating thyroid hormone, the latter measured by protein-bound iodine (PBI), increased T4 levels (by column or radioimmunoassay) or T3 levels (by radioimmunoassay). The T3 resin uptake decreased, reflecting the increase in TBG. Free T3 and free T4 concentrations remained unchanged. 3. Other binding proteins in serum, namely corticosteroid binding globulin (CBG) and gonadal hormone binding globulin (SHBG), may increase, increasing circulating corticosteroids and sex steroids, respectively. Free and biologically active hormone concentrations remain unchanged. Other plasma proteins may also increase (angiotensinogen/renin substrate, alpha 1 antitrypsin, ceruloplasmin). 4. HDL and HDL-2 concentrations increase, LDL-cholesterol concentration decreases, and TG levels increase. 5. Glucose tolerance decreases. 6. Decreased response to metyrapone test. 7. Decreased serum folate concentration.